Literature DB >> 16543540

Frequency of dystrophic muscle abnormalities in chronic progressive external ophthalmoplegia: analysis of 86 patients.

B H Kiyomoto1, C H Tengan, C K Costa, A S Oliveira, B Schmidt, A A Gabbai.   

Abstract

BACKGROUND: There are few reports describing the coexistence of dystrophic features with those typical of mitochondrial myopathies in muscle biopsy. A recent study suggested that dystrophic features are frequent in patients with chronic progressive external ophthalmoplegia (CPEO) with a high mutation load, but the actual frequency of these abnormalities in CPEO remains undetermined.
OBJECTIVE: To review the occurrence of dystrophic abnormalities in a large series of patients with CPEO to assess the frequency of such abnormalities and to verify whether they are correlated with specific mitochondrial DNA (mtDNA) mutations.
METHODS: Retrospective survey of case series (86 patients with CPEO).
RESULTS: Only three cases with dystrophic abnormalities were found: two with a large scale mtDNA deletion and one with the A3251G mutation. All three patients showed predominantly proximal muscular weakness resembling limb girdle muscular dystrophy.
CONCLUSIONS: Dystrophic abnormalities are rare in CPEO and are not correlated with a specific molecular defect.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16543540      PMCID: PMC2077486          DOI: 10.1136/jnnp.2005.079954

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  14 in total

Review 1.  Oxidative phosphorylation disease diagnosis.

Authors:  J M Shoffner
Journal:  Ann N Y Acad Sci       Date:  1999       Impact factor: 5.691

2.  A tRNA(Ala) mutation causing mitochondrial myopathy clinically resembling myotonic dystrophy.

Authors:  R Horváth; H Lochmüller; C Scharfe; B H Do; P J Oefner; J Müller-Höcker; B G Schoser; D Pongratz; D P Auer; M Jaksch
Journal:  J Med Genet       Date:  2003-10       Impact factor: 6.318

3.  Extraocular muscle is spared despite the absence of an intact sarcoglycan complex in gamma- or delta-sarcoglycan-deficient mice.

Authors:  J D Porter; A P Merriam; A A Hack; F H Andrade; E M McNally
Journal:  Neuromuscul Disord       Date:  2001-03       Impact factor: 4.296

4.  New insights into the metabolic consequences of large-scale mtDNA deletions: a quantitative analysis of biochemical, morphological, and genetic findings in human skeletal muscle.

Authors:  R Schröder; S Vielhaber; F R Wiedemann; C Kornblum; A Papassotiropoulos; P Broich; S Zierz; C E Elger; H Reichmann; P Seibel; T Klockgether; W S Kunz
Journal:  J Neuropathol Exp Neurol       Date:  2000-05       Impact factor: 3.685

5.  Progression of myopathology in Kearns-Sayre syndrome: a morphological follow-up study.

Authors:  H Reichmann; R Gold; B Meurers; M Naumann; P Seibel; U Walter; T Klopstock
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

6.  Diagnostic criteria for the limb-girdle muscular dystrophies: report of the ENMC Consortium on Limb-Girdle Dystrophies.

Authors:  K M Bushby
Journal:  Neuromuscul Disord       Date:  1995-01       Impact factor: 4.296

7.  A new mitochondrial tRNA(Met) gene mutation in a patient with dystrophic muscle and exercise intolerance.

Authors:  J Vissing; M B Salamon; P Arlien-Søborg; S Nørby; P Manta; S DiMauro; H Schmalbruch
Journal:  Neurology       Date:  1998-06       Impact factor: 9.910

Review 8.  Mitochondrial encephalomyopathies: clinical and molecular analysis.

Authors:  E A Schon; M Hirano; S DiMauro
Journal:  J Bioenerg Biomembr       Date:  1994-06       Impact factor: 2.945

9.  Contrasting histochemical features of various mitochondrial syndromes.

Authors:  S Collins; E Byrne; X Dennett
Journal:  Acta Neurol Scand       Date:  1995-04       Impact factor: 3.209

10.  Muscle structural changes in mitochondrial myopathy relate to genotype.

Authors:  David B Olsen; Annika R Langkilde; Mette C Ørngreen; Eigil Rostrup; Marianne Schwartz; John Vissing
Journal:  J Neurol       Date:  2003-11       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.